Durability of Efficacy and Safety of Roflumilast Cream 0.3% in Adults With Chronic Plaque Psoriasis From a 52-Week, Phase 2 Open-Label Safety Trial. J of Skin 2023, 7 (4), s218. https://doi.org/10.25251/skin.7.supp.218.